Filing Details
- Accession Number:
- 0001209191-19-009138
- Form Type:
- 4
- Zero Holdings:
- No
- Publication Time:
- 2019-02-11 19:53:42
- Reporting Period:
- 2019-02-07
- Accepted Time:
- 2019-02-11 19:53:42
- SEC Url:
- Form 4 Filing
Issuer
| Cik | Name | Symbol | Sector (SIC) | IRS No |
|---|---|---|---|---|
| 1131324 | Genomic Health Inc | GHDX | Services-Medical Laboratories (8071) | 770552594 |
Insiders
| Cik | Name | Reported Address | Insider Title | Director | Officer | Large Shareholder | Other |
|---|---|---|---|---|---|---|---|
| 1649689 | J James Vaughn | 301 Penobscot Drive Redwood City CA 94063 | Chief Commercial Officer | No | Yes | No | No |
Reported Non-Derivative Transactions
| Sec. Name | Acquisiton - Disposition | Date | Amount | Price | Remaning Holdings | Equity Swap Involved | Form Type | Code | Nature of Ownership | Explanation |
|---|---|---|---|---|---|---|---|---|---|---|
| Common Stock | Acquisiton | 2019-02-07 | 3,000 | $31.12 | 27,125 | No | 4 | M | Direct | |
| Common Stock | Disposition | 2019-02-07 | 2,050 | $77.19 | 25,075 | No | 4 | S | Direct | |
| Common Stock | Disposition | 2019-02-07 | 950 | $77.94 | 24,125 | No | 4 | S | Direct |
| Equity Swap Involved | Form Type | Code | Nature of Ownership | Explanation |
|---|---|---|---|---|
| No | 4 | M | Direct | |
| No | 4 | S | Direct | |
| No | 4 | S | Direct |
Reported Derivative Transactions
| Sec. Name | Sec. Type | Acquisiton - Disposition | Date | Amount | Price | Amount - 2 | Price - 2 |
|---|---|---|---|---|---|---|---|
| Common Stock | Employee Stock Option (right to buy) Holding | Disposition | 2019-02-07 | 3,000 | $0.00 | 3,000 | $31.12 |
| Remaning Holdings | Exercise Date | Expiration Date | Equity Swap Involved | Transaction Form Type | Transaction Code | Nature of Ownership |
|---|---|---|---|---|---|---|
| 26,835 | 2025-02-13 | No | 4 | M | Direct |
Footnotes
- Includes an aggregate of 19,674 shares of common stock issuable pursuant to previously reported restricted stock units that have not vested.
- These sales of common stock were effected pursuant to Rule 10b5-1 sales plan adopted by the reporting person on August 6, 2018.
- Reporting person undertakes to provide upon request by the Securities and Exchange Commission, the issuer or a securityholder of the issuer detailed information regarding the price and number of shares sold within the range indicated.
- Represents weighted average sale price. Actual sale prices ranged from $76.63 to $77.62.
- Represents weighted average sale price. Actual sale prices ranged from $77.63 to $78.30.
- The option became exercisable as to 25% of the shares on February 13, 2016, and becomes exercisable as to 1/48th of the shares each full month thereafter.
Billionaire Hedge Funds
